Recombinant human thrombopoietin treatment in patients with chronic liver disease-related thrombocytopenia undergoing invasive procedures: A retrospective study

Table 1 Patient baseline characteristics

Characteristic	Count (%)
Male	59 (59.00)
Age	58.48 ± 13.90
Etiology
Hepatitis B related CLD	38 (38.00)
Hepatitis C related CLD	3 (3.00)
Schistosome related CLD	16 (16.00)
Autoimmune liver disease	14 (14.00)
Alcoholic liver disease	5 (5.00)
Liver tumors	14 (14.00)
Drug induced CLD	2 (2.00)
Liver abscess	1 (1.00)
Chronic liver failure	1 (1.00)
Budd Chiari syndrome	1 (1.00)
CLD of unknown origin	5 (5.00)
Child-Pugh grades
Grade A (5-6 points)	8 (8.00)
Grade B (7-9 points)	48 (48.00)
Grade C (10-15 points)	44 (44.00)
Different platelet counts (× 109/L)
Group I (< 30)	25 (25.00)
Group II (30-50)	43 (43.00)
Group III (> 50)	32 (32.00)
Medication duration
Group A ( 7 d)	31 (31.00)
Group B (8-14 d)	38 (38.00)
Group C (15-21 d)	22 (22.00)
Group D (22-28 d)	9 (9.00)
No platelet transfusion	90 (90.00)
Side effect
Fever	2 (2.00)
Fatigue and anorexia	4 (4.00)

CLD: Chronic liver disease.